アレルギー性喘息に関連したデンドリット細胞媒介型2型免疫反応と呼吸道炎症を抑制するためにADAM17を標的とする
Anil Kumar Jaiswal1, Dmitriy Minond2, Amarjit Mishra3
1BioLegend, SanDiego, CA, USA.
Scientific reports
|August 25, 2025
まとめ
アレルギー性喘息において,ADAM17 (分解タンパク質とメタルプロテインーゼ17ドメイン) が重要な役割を果たします. 樹状細胞におけるADAM17を阻害することで,呼吸道炎症が軽減され,マウスは喘息の症状から保護されました.
科学分野:
- 免疫学
- アレルギー研究
- マトリックスメタロプロテインゼ
背景:
- ADAM17 (a disintegrin and metalloproteinase domain 17) は,生物学的プロセスを調節する亜鉛を含む酵素である.
- ADAM17は,その広範な基板プロファイルにより,炎症と適応免疫に影響を与えます.
- 2型アレルギー性喘息の病原性におけるADAM17の特定の役割は,ほとんど研究されていない.
研究 の 目的:
- 家粉虫 (HDM) によって引き起こされる呼吸道炎症と適応免疫反応におけるADAM17のインビボの役割を調査する.
- アレルギー性喘息に対する dendritic cell-specific ADAM17 deletion (ΔDC) の影響を評価する.
- マウスモデルで新しい小分子ADAM17阻害剤 (2155-17) の有効性を評価する.
主な方法:
- dendritic cell-specific ADAM17欠乏したマウス (ΔDC) の生成
- ハウスダストミット (HDM) 曝露によるアレルギー性呼吸道炎症の誘導
- 新型小分子ADAM17阻害剤 (2155-17) の投与
- 呼吸道過剰反応 (AHR),エオシノフィルの偏化,免疫細胞機能の評価
主要な成果:
- dendritic cell-specific ADAM17 ablation (ΔDC) は2型/エオシノフィルのアレルギー反応を著しく抑制し,AHRから保護しました.
- ADAM17欠乏の dendritic 細胞は,代謝活動が低下し,免疫原始化が低下し,アレルゲン固有の2型細胞の偏化が抑制された.
- 2型/エオシノフィルのHDM誘発性アレルギー反応から保護された野生型のマウスにADAM17阻害剤2155-17を鼻内投与した.
結論:
- ADAM17は2型アレルギー性喘息の呼吸道炎症を媒介する上で重要な役割を果たします.
- 選択性小分子阻害剤でADAM17を標的にすることは,2型高度アレルギー性喘息の潜在的治療戦略です.
関連する概念動画
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
453
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
453
01:19Antiasthma Drugs: Leukotriene Modifiers
463
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
463
01:20Asthma: Pathogenesis and Management
581
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
581
01:17Drugs Used in Lower Respiratory Disorders: Overview
578
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
578
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
380
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
380
01:26Asthma-II: Pathophysiology and Classification
2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K